Cargando…
Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851376/ https://www.ncbi.nlm.nih.gov/pubmed/36686842 http://dx.doi.org/10.3389/fonc.2022.1098375 |
| _version_ | 1784872383242305536 |
|---|---|
| author | Thomas, Colin Thapa, Sameep McLaughlin, Connor Halloran, Molly Porcu, Pierluigi |
| author_facet | Thomas, Colin Thapa, Sameep McLaughlin, Connor Halloran, Molly Porcu, Pierluigi |
| author_sort | Thomas, Colin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9851376 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98513762023-01-20 Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma Thomas, Colin Thapa, Sameep McLaughlin, Connor Halloran, Molly Porcu, Pierluigi Front Oncol Oncology Frontiers Media S.A. 2023-01-04 /pmc/articles/PMC9851376/ /pubmed/36686842 http://dx.doi.org/10.3389/fonc.2022.1098375 Text en Copyright © 2023 Thomas, Thapa, McLaughlin, Halloran and Porcu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Oncology Thomas, Colin Thapa, Sameep McLaughlin, Connor Halloran, Molly Porcu, Pierluigi Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma |
| title | Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma |
| title_full | Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma |
| title_fullStr | Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma |
| title_full_unstemmed | Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma |
| title_short | Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma |
| title_sort | point and counterpoint: polatuzumab vedotin in the front-line therapy for diffuse large b- cell lymphoma |
| topic | Oncology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851376/ https://www.ncbi.nlm.nih.gov/pubmed/36686842 http://dx.doi.org/10.3389/fonc.2022.1098375 |
| work_keys_str_mv | AT thomascolin pointandcounterpointpolatuzumabvedotininthefrontlinetherapyfordiffuselargebcelllymphoma AT thapasameep pointandcounterpointpolatuzumabvedotininthefrontlinetherapyfordiffuselargebcelllymphoma AT mclaughlinconnor pointandcounterpointpolatuzumabvedotininthefrontlinetherapyfordiffuselargebcelllymphoma AT halloranmolly pointandcounterpointpolatuzumabvedotininthefrontlinetherapyfordiffuselargebcelllymphoma AT porcupierluigi pointandcounterpointpolatuzumabvedotininthefrontlinetherapyfordiffuselargebcelllymphoma |